



Lyka Labs Limited

MANUFACTURERS OF PHARMACEUTICALS.

Regd. Office: 4801/B & 4802/A, GIDC Industrial Estate, Ankleshwar-393002.
Administrative Office: 101, Shiv Shakti Industrial Estate, Andheri-Kurla Rd., Andheri (East), Mumbai -400059.

UNAUDITED FINANCIAL RESULTS [PROVISIONAL] OF QUARTER ENDED 31ST MARCH, 2008

(Rs. in Lacs)

	Quarter Ended 31.03.2008 (Unaudited)	Quarter Ended 31.03.2007 (Unaudited)	12 Months Ended 31.03.2008 (Unaudited)	18 Months Ended 31.03.2007 (Audited)
1. Net Sales/Income from operations	2941.54	2691.90	11241.66	13427.79
2. Other Income	55.91	78.26	348.67	987.08
3. Total Expenditure				
(a) (Increase)/Decrease in Stock in Trade	321.41	(68.26)	88.17	(82.82)
(b) Consumption of Materials	1689.68	1817.73	6438.34	8955.58
(c) Staff Cost	226.83	139.42	733.95	847.77
(d) Other Expenditure (Incl. Excise Duty)	467.90	617.95	2811.72	3244.83
	2705.82	2506.84	10072.18	12965.36
4. Operational Profit / (Loss) before Interest, Depreciation and Taxation	291.63	263.32	1518.15	1449.51
5. Interest & Finance Cost	163.43	159.17	691.81	874.88
6. Depreciation	44.22	43.63	178.48	213.19
7. Profit / (Loss) before Tax (4-5-6)	83.98	60.52	647.86	361.44
8. Bad Debts/Advances Written off	-	1761.56	-	1,761.56
9. Exchange Rate Fluctuation	169.80	0.00	169.80	102.65
10. Loss on Investment	-	-	-	368.00
11. Earlier Year Taxes	0.50	0.00	(1.05)	(119.20)
Provision for Tax (FBT)	6.00	3.00	15.00	13.98
12. Net Profit / (Loss) (7-8-9-10-11)	(92.32)	(1704.04)	464.11	(1765.55)
13. Paid-up Equity Share Capital (Face Value Rs.10/- per Share)	2093.00	1527.50	2093.00	1527.50
Paid up Pref. Share Capital (Face Value Rs. 100/- per Share)	108.57	108.57	108.57	108.57
14. Reserves excluding Revaluation Reserve				2,782.70
15. Earning Per Share on PBT (Rs.) (Basic & Diluted)	(0.39)	0.43	1.93	(12.53)
16. Aggregate of Non-promoter Share-holding				
Number of Shares	16,552,735	11,892,785	16,552,735	11,892,785
Percentage of Shareholding	79.09	77.86	79.09	77.86

Notes:

1. The above results, were duly considered by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on 30th April, 2008.
2. The Company has one Single Segment "Pharmaceuticals".
3. Net sales / Income from operations include Processing Charges of Rs. 352.90 Lacs.
4. During the quarter, the Company has allotted on a preferential basis 5,20,000 Equity Shares of Rs.10/- each at a premium of Rs. 45/- per share on conversion of 5,20,000 Equity Warrants and 2,75,000 Equity Shares of Rs. 10/- each at a premium of Rs. 31.50 per share on conversion of 2,75,000 Equity Warrants.
5. No depreciation has been provided in respect of revalued Assets for Building and Plant & Machinery during the quarter.
6. No complaint of Investors received during the quarter.
7. Previous period/quarter figures have been regrouped wherever necessary.
8. Audit qualifications in respect of Audited Accounts for 2005-07 and management comments thereon are detailed below:
 - I. The deferment of R & D expenditure of Rs.1,61,14,667/- & GDR Issue expenses of Rs. 91,61,542/- which is not in compliance with Accounting Standard (AS-26). The Company has explained at note No. 15 to the accounts.
 - II. Regarding non-provision of arrears of ex-gratia at Rs.3,66,69,307/-, the matter presently is subjudice.

Place : Mumbai
Dated : 30th April, 2008

For **LYKA LABS LIMITED**
(N. I. GANDHI)
Chairman & Managing Director

PRESSMAN